Product Description
Sufentanil is an anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid. It has a role as an opioid analgesic, a mu-opioid receptor agonist, an anaesthesia adjuvant and an intravenous anaesthetic. It is a member of piperidines, a member of thiophenes, an anilide and an ether.
Mechanisms of Action: OPRM Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Sublingual,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Austria | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Morocco | Netherlands | Norway | Peru | Poland | Portugal | Romania | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Ukraine | United Kingdom | United States | Vietnam
Approved Indications: Pain Unspecified | Substance Abuse Unspecified
Known Adverse Events: Hypotension | Dizziness | Headache
Company: Melinta
Company Location: MORRISTOWN NJ 07963
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Denmark, New Zealand, Unknown Location
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Acute Pain
Phase 2: Healthy Volunteers
Phase 1: COVID-19|Chronic Pain|Common Cold
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PDC 01-0205 | P3 |
Completed |
Acute Pain |
2023-10-05 |
95% |
| PDC 01-0205 | P3 |
Completed |
Acute Pain |
2023-10-05 |
95% |
| 2021-003258-21 | P2 |
Active, not recruiting |
Healthy Volunteers |
2023-05-19 |
|
| CTR20223204 | P1 |
Completed |
Chronic Pain |
2023-04-17 |
|
| WBP01-AT004952 | P1 |
Not yet recruiting |
COVID-19|Common Cold |
2020-08-31 |